Cantabio Pharmaceuticals Inc., has entered into a licensing agreement with Cambridge Enterprise Limited that provides Cantabio an access to intellectual property from research targeting the Tau protein for the treatment of Tauopathies such as Alzheimer's disease (AD) and Dementia. The aggregation of Tau is a hallmark of Tauopathies and is linked to the onset and progression of these diseases. The licensed therapeutic program contains data and know-how for a set of novel, small molecule drug candidates that bind to the Tau protein and reduce its misfolding and aggregation. Under the terms of the transaction, Cantabio will get the full use of the program data and the right to develop compounds derived from the research into therapies.